Condition
IBS-D (Diarrhea-predominant)
Total Trials
5
Recruiting
2
Active
2
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (2)
P 2 (1)
P 3 (1)
P 4 (1)
Trial Status
Completed2
Recruiting2
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07574320Phase 4Not Yet RecruitingPrimary
Effect of Ramosetron in Patients With Diarrhea Predominant Irritable Bowel Syndrome
NCT06727422Phase 2Recruiting
Efficacy of Rifaximin With NAC in IBS-D
NCT07520422Not ApplicableCompletedPrimary
Bacillus Coagulans Based Product in IBS-Diarrhea
NCT07168434Phase 3Recruiting
Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome
NCT06676514Not ApplicableCompletedPrimary
Study to Evaluate the Treatment Benefits of Probiotic Clostridium Butyricum CBM588® for IBS-D
Showing all 5 trials